Acuitas Therapeutics Announces Oral Presentations and Poster Sessions at BioChina and Vaccine Innovation Forum

Vancouver, B.C. – Acuitas Therapeutics, the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, today announced its participation in two upcoming conferences in China: BioChina and the Vaccine Innovation Forum (VIF). The company will showcase its industry-leading LNP delivery platform and its advancements in multi-valent and cancer vaccine applications through a series of oral presentations and poster sessions.  “Acuitas is dedicated to advancing mRNA-LNP technology through robust scientific validation and expanding its role in next-generation vaccines and therapeutics,” said Tom Madden, CEO of Acuitas Therapeutics. “Our participation in BioChina and the Vaccine Innovation Forum reflects our commitment to the global biotech ecosystem and our belief that the most transformative RNAbased medicines can be realized through international partnerships that unite world-class delivery technology with groundbreaking science.” Vaccine Innovation Forum (VIF) 2026 Shanghai, March 11 – 14, 2026  ● Oral Presentation: mRNA-Lipid Nanoparticles (LNP) for Cancer Vaccine Applications ○ Presenter: Sean Semple, Vice President, Preclinical Research  ○ Session: Cancer Vaccine and Immunotherapy  ○ Date: March 11, 2026  ● Oral Presentation: Next Generation Lipid Nanoparticles (LNP) for Multi-Valent Vaccines ○ Presenter: Tom Madden, CEO  ○ Session: RNA Technologies  ○ Date: March 12, 2026  ● Poster Presentation: Novel Lipids with Improved Activity for Prophylactic Vaccine Development ○ Presenter: Tom Madden, CEO  ○ Date: March 11, 2026  BioChina Suzhou, March 12 – 14, 2026 ● Oral Presentation: Optimizing Lipid Nanoparticles for Clinical Applications of mRNA Therapeutics  ○ Presenter: Sean Semple, Vice President, Preclinical Research  ○ Session: RNA Delivery and Future Applications ○ Date: March 14, 2026  More information about the conferences can be found on the Vaccine Innovation Forum and BioChina websites.   About Acuitas Therapeutics Acuitas Therapeutics Inc., the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, is a Vancouver-based company collaborating with pharmaceutical and biotech companies, academic researchers, and global health organizations to advance a broad range of medicines for a variety of diseases.   Acuitas’ clinically validated LNP technology has had a profound global impact — most notably enabling the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, which has protected billions of people in more than 180 countries. Its technology also enables ONPATTRO® by Alnylam Pharmaceuticals, the first FDA-approved RNAi therapeutic for treating the rare and fatal disease transthyretin amyloidosis. More recently, Acuitas’ LNP technology has delivered other groundbreaking firsts: the first in-human proof of concept for genome base editing and the first personalized CRISPR therapy.  Today, Acuitas is advancing next-generation LNP to support a variety of therapeutic modalities. This includes targeted LNP for extrahepatic and in vivo CAR T-cell therapies, epigenetic medicines to modulate gene expression without altering DNA, and multivalent vaccines for infectious diseases — such as malaria, HIV/AIDS, and tuberculosis — as well as oncology vaccines, including personalized cancer vaccines.   For more information, visit www.acuitastx.com. -END- Media Contact: Jakub Cikowski HDMZ acuitas.pr@hdmz.com